In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “SITC Living Guidelines” rapid update protocols designed to ensure SITC’s CPGs are up-to-date with cutting-edge thinking and incorporate the leading expert guidance in cancer immunotherapy care – a vital service to treating clinicians and those along the whole cancer care continuum.
Rapid Update v1.2 Summary
The information below provides an overview of update v1.2 to the "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer" published in Journal for ImmunoTherapy of Cancer (JITC).
- The FDA granted accelerated approval for dostarlimab for the treatment of dMMR recurrent or advanced solid tumors (along with the VENTANA MMR RxDx Panel companion diagnostic to detect dMMR) that have progressed on or following prior treatment and who have no satisfactory alternative treatment options on August 17, 2021. Based on these approvals, the Breast Cancer CPG has been updated in the following locations: "Immunotherapy with PD-(L)1 Inhibitors for the Treatment of Advanced/Metastatic Breast Cancer" and "Diagnostics and Biomarker Testing in Patients with Advanced/Metastatic Breast Cancer." Additionally, Table 2 was updated from the original publication to include the GARNET trial data that led to the tissue-agnostic dostarlimab approval.
- The FoundationOne CDx assay was approved as the companion diagnostic for identifying patients with MSI-H tumors for treatment with pembrolizumab in February 2022. Based on this approval, the Breast Cancer CPG has been updated in the following location: "Diagnostics and Biomarker Testing in Patients with Advanced/Metastatic Breast Cancer."
How to View the Living Guideline Rapid Update
Through the use of an innovative technology, rapid updates are swiftly integrated into our existing published guidelines in a clear and concise manner. An overlay system highlights affected content and provides new text reflecting the updated Expert Panel guidance as well as important supporting information, data, and references, as applicable. These rapid updates show the progression of the changes by using a version numbering system that accompanies each new posted update.
For More Information
- SITC Breast Cancer CPG – Overview of all available updates and companion guideline educational offerings for this guideline
- SITC Guidelines Program – Listing of all published guidelines in the SITC CPG catalogue and more about the SITC Living Guidelines rapid updates
- Follow us on social media – #SITCGuidelines on “X” and LinkedIn
- Questions – Contact a member of the SITC guideline development staff at scientificresources@sitcancer.org